Tarloxotinib Bromide

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameTarloxotinib Bromide
Drug Alias Name溴他替尼Tarloxotinibi bromidumTarlox溴化他罗替尼Bromure de tarloxotinib +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThreshold
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRain Oncology IncRain Therapeutics IncMedical University Of South Carolina +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksN/A